Federated Hermes Inc. Has $2.76 Million Stock Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS)

Federated Hermes Inc. reduced its position in Gossamer Bio, Inc. (NASDAQ:GOSS) by 2.2% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 3,065,136 shares of the company’s stock after selling 67,978 shares during the period. Federated Hermes Inc.’s holdings in Gossamer Bio were worth $2,762,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Sivia Capital Partners LLC acquired a new stake in Gossamer Bio in the first quarter worth about $29,000. SG Americas Securities LLC bought a new stake in shares of Gossamer Bio during the first quarter worth approximately $34,000. Choreo LLC acquired a new position in Gossamer Bio in the second quarter valued at approximately $46,000. Sequoia Financial Advisors LLC boosted its stake in Gossamer Bio by 27.2% in the second quarter. Sequoia Financial Advisors LLC now owns 93,500 shares of the company’s stock valued at $84,000 after acquiring an additional 20,000 shares during the last quarter. Finally, Financial Advocates Investment Management grew its holdings in Gossamer Bio by 35.0% during the 4th quarter. Financial Advocates Investment Management now owns 98,350 shares of the company’s stock worth $90,000 after acquiring an additional 25,500 shares during the period. Institutional investors own 81.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on GOSS. The Goldman Sachs Group reissued a “buy” rating and issued a $8.00 price target on shares of Gossamer Bio in a research note on Monday, June 17th. Wedbush restated an “outperform” rating and set a $4.00 target price on shares of Gossamer Bio in a report on Tuesday, August 13th. Oppenheimer initiated coverage on Gossamer Bio in a research note on Tuesday, June 25th. They issued an “outperform” rating and a $9.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Gossamer Bio in a research note on Tuesday. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Gossamer Bio currently has an average rating of “Buy” and an average target price of $9.20.

Gossamer Bio Stock Up 5.3 %

Shares of Gossamer Bio stock opened at $0.96 on Friday. The company has a market capitalization of $217.12 million, a P/E ratio of -0.91 and a beta of 1.95. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.21 and a quick ratio of 8.21. The business has a 50-day moving average of $0.93 and a two-hundred day moving average of $0.92. Gossamer Bio, Inc. has a 1 year low of $0.45 and a 1 year high of $1.60.

Gossamer Bio (NASDAQ:GOSS) last announced its earnings results on Monday, August 12th. The company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.23 by ($0.01). The business had revenue of $95.84 million for the quarter, compared to analysts’ expectations of $160.00 million. As a group, equities analysts predict that Gossamer Bio, Inc. will post -0.33 EPS for the current year.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.